- Policy
- HIRA rejects reimbursed use of Spinraza on 14-year-old
- by Lee, Hye-Kyung Dec 3, 2019 05:53am
- Approval on reimbursed use of Spinraza (nusinersen) on a 14-year-old male patient with 5q spinal muscular atrophy (SMA) was denied. The application submitted by the hospital was rejected as it did not clarify if the patient had developed clinical symptoms of SMA before 36 months. On Nov. 29, Health Insurance Review and Assessment (HIRA,
- Policy
- Stivarga's price-volume agreement, 3.2% down
- by Kim, Jung-Ju Dec 3, 2019 05:53am
- Bayer Korea's Stivarga 40mg is targeted for price-volume agreement linkage and has been negotiated with the National Health Insurance Service. Lartruvo inj will be reduced to &8361;10,394,464 from February 1 2022. Daewoong Pharmaceutical's 10 mg and 30 mg of Aliga Capsules are listed at &8361;3,703 and &8361;7,408, respectively, bas
- Company
- Drug Committees pass oral Fabry treatment Galafold
- by Eo, Yun-Ho Dec 2, 2019 05:57am
- The world’s first orally taken Fabry disease treatment ‘Galafold’ is landing its code on tertiary hospital drug list. According to pharmaceutical industry, Handok’s Galafold (migalastat) has been passed by drug committees (DC) in specialized healthcare institutes for rare disease care, like Seoul Asan Medical Center, Ajou University
- Policy
- Reimbursement standards expanded ADHD combined & Somatropin
- by Kim, Jung-Ju Dec 2, 2019 05:56am
- From next month, the combination of treatment with attention-deficit hyperactivity disorder (ADHD), which differs in the mechanism of action, and the reinforcement reimbursement standards for growth hormones such as Somatropin, etc., will expand and insurance coverage will be widened. The reimbursement criteria for Somatropin injections are
- Policy
- 'Ongentys' by SK Chemicals approved in Korea
- by Lee, Tak-Sun Dec 2, 2019 05:56am
- SK Chemicals obtained a domestic item approval for Parkinson's disease treatment,‘ Ongentys Capsule (Opicapone)’. This product is expected to be a new drug in the Parkinson's disease market after a long interval. The Ministry of Food and Drug Safety approved the marketing of SK Chemicals 'Ongentys Capsule 25mg, 50mg' on the 26th. Thi
- Policy
- Generics for Galvus, focus on development strategy
- by Lee, Tak-Sun Dec 2, 2019 05:56am
- The development of generic drugs for Galvus (Vildagliptin by Novatis Korea), which is a DPP-4 inhibitor for diabetes mellitus is continuing. In particular, while Ahn-gook pharmaceuticals and Hanmi Pharmaceuticals have already completed their commercialization and anticipated market preoccupation, pharmaceutical companies' strategies to pe
- Policy
- “Cost-effectiveness review inevitable for high-cost drugs”
- by Lee, Jeong-Hwan Nov 30, 2019 05:51am
- Korean Minister of Health and Welfare Park Neung-hoo stated the ministry would approach the issue of National Health Insurance (NHI) coverage on super expensive drugs by evaluating cost-effectiveness of treatment and pharmaceutical opportunity cost. Particularly, Minister Park highlighted insurance covered drug pricing system in Korea i
- Policy
- NHI billing soars and brings down Xeljanz price by 9%
- by Eo, Yun-Ho Nov 30, 2019 05:50am
- Starting from next month, reimbursed price of Pfizer Korea’s Janus kinase (JAK) inhibitor Xeljanz (5 mg) is to be lowered by 9 percent. The treatment is now included as subject for price-volume agreement (PVA), because the actual insurance billing amount was surged by 30 percent than the initially estimated amount. Also for Allergan Korea
- Company
- The Answer is in RSA expansion and undisclosed pricing
- by Kim, Jung-Ju Nov 29, 2019 10:54pm
- Maybe the answer has been before our very eyes all along. If Korea Passing occurs when other foreign countries start referring to Korean drug pricing, then it could be avoided by preventing them from referencing. Otherwise, drug could be price at a moderate level to avoid Korea Passing regardless of other countries. Theoretically t
- Policy
- Price competition for Donepezil’s generics is high
- by Kim, Jung-Ju Nov 29, 2019 07:06am
- Pharmaceutical companies with Donepezil have lowered their reimubrsement premium caps and intensified price competition. This time, drugs that voluntarily lowered were dropped from 36% to 67% below the current price. This would be less than one-third of the highest price. LG Chem's three lines of Eutropin are expected to be subject to addi
